[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-failure-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-failure-chronic":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,77,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100345533","enhancing-renal-graft-function-during-donor-anesthesia-100345533",false,"NCT03778944","Enhancing Renal Graft Function During Donor Anesthesia","Renal Graft Functional Enhancement During Donor Anesthesia: A Comparative Study of 3 Modalities","Inclusion Criteria:\n\n* end-stage renal disease, for living-donor kidney transplantation\n\nExclusion Criteria:\n\n* severe cardiac or hepatic dysfunction\n* coagulopathy","ALL","18 Years","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess \\& compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.",[27,28,29],"Renal Failure Chronic","Transplant;Failure,Kidney","Anesthesia",[31,32,33,34,29],"Mannitol","Dopamine","Perfusion","Renal graft donor","RECRUITING","2026-01-08",{"date":38,"type":39},"2026-01-12","ACTUAL",{"date":41,"type":39},"2018-12-20",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"Nazmy Edward Seif","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100573768","study-to-examine-the-effect-of-the-diuretic-furosemide-on-the-plasma-levels-of-toxins-and-the-removal-of-toxins-from-the-blood-in-patients-with-chronic-kidney-disease-100573768","NCT06750575","Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease","The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease","FUROPBUT","Inclusion Criteria:\n\n* An age of 18 years or older\n* An eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2 for at least three months (diagnosis of CKD stage 3-5)\n* An indication for the start of treatment with furosemide as part of routine patient care\n* Willingness to participate in the study and a signed informed consent\n\nExclusion Criteria:\n\n* Patients who are already on furosemide treatment\n* Patients with a liver disease with hyperbilirubinemia\n* Patients who receive any type of renal replacement therapy (peritoneal dialysis, haemodialysis)\n* Patients with end-stage renal failure without residual diuresis\n* Patients who will start with medication simultaneously with start of furosemide treatment that might interfere with PBUT excretion or PBUT protein binding\n* Patients who are incapacitated",{"count":57,"type":21},34,"OBSERVATIONAL","The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine.\n\nParticipants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following:\n\n* Blood pressure measurement\n* Blood sample withdrawal\n* Urine sample collection\n* 12-hour urine collection\n\nThen, one to four weeks after starting with furosemide treatment, patients will undergo the following:\n\n* Blood pressure measurement\n* Blood sample prior to furosemide intake (Tmin)\n* Blood sample withdrawal 90 minutes after furosemide intake (Tmax: time at which the highest furosemide plasma level is expected)\n* Urine sample collection 60-120 minutes after furosemide intake\n* 12-hour urine collection\n\nThe investigators expect furosemide to increase plasma levels of PBUTs by decreasing the renal excretion of the toxins.",[61,27],"Chronic Kidney Diseases",[63,64,65,66,67],"Furosemide","Drug-toxin interactions","Protein-bound uremic toxins","P-cresyl sulfate","Indoxyl sulfate","2024-12-19",{"date":70,"type":39},"2024-12-27",{"date":72,"type":39},"2024-06-10",{"date":74,"type":21},"2025-07-01",{"name":76,"class":46},"UMC Utrecht",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":47},"100568147","endovascular-preparation-for-kidney-tranplantation-100568147","NCT06677437","Endovascular Preparation for Kidney Tranplantation","EndoPreKiT","Inclusion Criteria:\n\n1. Patient from 18 to 85 years old (beyond 85 years old, guidance must remain exceptional)\n2. Patients with chronic renal failure\n3. Waiting for a kidney transplant\n4. Who have a vascular contraindication to renal transplantation because of their anatomical constraints.\n\nExclusion Criteria:\n\n1-All criteria contraindicating kidney transplant other than for arterial anatomical problems: All criteria contraindicating kidney transplant other than for arterial anatomical problems:\n\n* A progressive cancer, which is not cured,\n* An uncontrolled infectious disease,\n* Severe cardiovascular or respiratory disease making general anesthesia impossible,\n* Unstabilized psychiatric disorders or illness,\n* Dementia proven to have progressed after specialist advice\n* Major obesity, with a body mass index greater than 50 kg\u002Fm2\n* Patient refusal 2. Patient under curatorship 3. Pregnant woman 4. Patients for whom it will not be possible to organize regular medical follow-up","85 Years",{"count":86,"type":21},58,"This national study is a feasibility study. It wants to validate all stages of the endovascular preparation of the iliac axis up to the kidney transplant for patients in whom the installation of a tailor-made endoprosthesis was necessary beforehand.\n\nThese patients are currently at a therapeutic impasse. This strategy of renal transplantation on an iliac artery endoprosthesis could ultimately give them access to the transplant with an improvement in quality of life and survival, for lower costs of care for the hospital and safety. less social than treatment by hemodialysis",[27,89],"Kidney Transplant","2024-11-05",{"date":92,"type":39},"2024-11-06",{"date":94,"type":39},"2024-01-01",{"date":96,"type":21},"2028-01-01",{"name":98,"class":46},"Hospices Civils de Lyon",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100560489","the-outcomes-of-living-donor-robotic-assisted-kidney-transplantation-100560489","NCT06577805","The Outcomes of Living Donor Robotic Assisted Kidney Transplantation","A Retrospective Cohort Study of Prospectively Collect the Outcomes of Recipients After Robot-assisted Kidney Transplantation","RAKT","Inclusion Criteria:\n\n1. living-donor kidney transplant recipients\n2. receiving standard triad immunosuppressive regimen\n\nExclusion Criteria:\n\n1. active infection\n2. multi-organ transplantation\n3. malignancy history in the donor and recipient\n4. human immunodeficiency virus infection","65 Years",{"count":109,"type":21},400,"The technology for robot-assisted kidney transplantation (RAKT) has become increasingly advanced, with numerous studies demonstrating comparable outcomes between RAKT surgery and open surgery. This advancement is particularly noteworthy as it extends its suitability to transplant patients with obesity. It will be important to explore the results of robot-assisted kidney transplantation as compared with open surgery or within cohorts.",[112,27],"Kidney Transplant; Complications",[114],"robotic surgery","2024-08-29",{"date":117,"type":39},"2024-09-03",{"date":119,"type":39},"2020-07-01",{"date":121,"type":21},"2025-12",{"name":123,"class":46},"West China Hospital","Renal Failure, Chronic"]